Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response

Kim A Papp; Joseph F Merola; Alice B Gottlieb; Et al.

doi:10.25251/skin.2.supp.93

Kim A Papp
Joseph F Merola
Alice B Gottlieb
Et al.

Keywords

Abstract

Abstract not available.

Disclosures: Study sponsored by UCB Pharma.

Poster PDF

Published

Dec 17, 2018

DOI https://doi.org/10.25251/skin.2.supp.93

How to Cite

Papp, K. A., Merola, J. F., Gottlieb, A. B., & al., E. (2018). Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response. SKIN The Journal of Cutaneous Medicine, 2, S92. https://doi.org/10.25251/skin.2.supp.93

Issue

Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Thomas Scharnitz, Kim Hoyt, Renata M Kisa, Subhashis Banerjee, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Abby Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al., Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Alice B Gottlieb, Bruce Strober, Diamant Tha?i, Kenneth Gordon, Sundeep Kundu, Renata Kisa, Lan Wei, Subhashis Banerjee, Joseph Merola, BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Andrew Blauvelt, Kim A Papp, Joseph F Merola, Alice B Gottlieb, Nancy Cross, Cindy Madden, Luke Peterson, Christopher Cioffi, Christopher EM Griffiths, Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Mark Lebwohl, Kim A Papp, Jashin J Wu, Andrew Blauvelt, Alan Menter, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel, Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Kim A Papp, Joseph F Merola, Alice B Gottlieb, Christopher EM Griffiths, Kristina K Harris, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt, Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Diamant Thaçi, Ron Vender, Menno de Rie, Curdin Conrad, Jennifer Soung, Bruce Strober, Maggie Wang, Nancy Cross, Delphine Deherder, Natalie Nunez Gomez, Alice B Gottlieb, Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Jeffrey Parno, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads, Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2 , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Kristian Reich, Andrew Blauvelt, Diamant Thaci, Craig Leonardi, Yves Poulin, Daniel Burge, Luke Peterson, Catherine Arendt, Alice B Gottlieb, Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Kim A Papp, Jensen Yeung, Neil Shear, Lorne Albrecht, Charles Lynde, Jingchuan Zhang, Yang Zhao, Jeff Parno, Alan M Mendelsohn, Melinda Gooderham, Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)

1 2 3 4 > >>

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Most read articles by the same author(s)